Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Comment by TheeRookon Dec 16, 2020 11:12am
177 Views
Post# 32118533

RE:RE:Quiet may be good

RE:RE:Quiet may be good The Test  turned out to have a fundamental flaw, not an advantage  to target the Spike protein while everyone else targeted the N Protein.     
 
 Then SONA claims to know more than the NML about virology saying NML is testing their test wrong because they are the only targeting the Spike protein..

 May seem obvious since the Spike protein is on the outside of the Virus.


AM: In the case of SARS-CoV-2, most serology tests are based on detecting antibodies against either the N protein or the S protein. Can you explain the differences between these two proteins and what makes them suitable as target antigens?

IV: Coronavirus has four main structural proteins: nucleocapsid (N), spike (S), membrane (M) and envelope (E). The S protein consists of the S1 and S2 subunits. The S protein is highly immunogenic since it is located on the surface of the virus.

The N protein plays an important role in the transcription and replication of viral RNA, packaging the encapsidated genome into virions and inhibits the cell cycle process of the host cells. The N protein is abundantly expressed during infections and also has high immunogenic activity. Therefore, both N and S protein could be potential targets for the antibody-based detection of SARS-CoV-2. However, the N protein homology between SARS-CoV-2 and SARSCoV-1 is 90 percent, compared with the S protein (77 percent), especially the S1 subunit including the RBD (66 percent).


MikeyH wrote: You really, really need to stop kidding yourself. If they can't get V1 past HC, they have absolutely zero chance with the saliva test (which is almost certain to be even more challenging wrt sensitivity). And as for the FDA, they didn't even get to the starting line!!

This is just bleed out slowly as the bagholders cling on, praying for a miracle that will never arrive.




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse